PETER ROST: PHARMA MARKETING EXPERT WITNESS. AWP, MEDICAL DEVICE EXPERT.: Bristol-Myers CEO MUST be crying like a baby now!
screen2largeMM

Dr. Rost provides services as a pharmaceutical marketing expert witness. For more info see: Drug Expert Witness. Dr. Peter Rost email. Copyright © 2006-2013 InSync Communication. All rights reserved. Terms of use agreement, privacy policy and the computer fraud and abuse act.
.

PETER ROST: PHARMA MARKETING EXPERT WITNESS. AWP, MEDICAL DEVICE EXPERT.

Peter Rost, M.D., is a former Pfizer Marketing Vice President providing services as a medical device and drug expert witness and pharmaceutical marketing expert. Judge Sanders: "The court agrees with defendants' view that Dr. Rost is a very adept and seasoned expert witness." He is also the author of Emergency Surgery, The Whistleblower and Killer Drug. You can reach him on rostpeter (insert symbol) hotmail.com. Please read the terms of use agreement and privacy policy for this blog carefully.

Bristol-Myers CEO MUST be crying like a baby now!

Peter Dolan, CEO of embattled BMS, who just got his office searched by the FBI, MUST be crying like a baby right now. Not because of the FBI raid, but because of what happened because of the deal he made that resulted in the FBI raid.

I first wrote about this story in How a small generic drug maker tricked the big guys into a deal that may land the big guys in jail.

BMS agreed to give the generic drug maker Apotex five days on the market before they would seek a preliminary injunction to stop Apotex, giving Apotex time it has used to flood drugstores with its version of Plavix.

In March this year, the parties announced a deal in which Bristol-Myers and Sanofi would pay Apotex a minimum of $40 million and give the company the right to sell generic Plavix months before their patent was set to expire in 2011.

Apotex said it was because they never believed the deal would be approved that they insisted on concessions if it was not.

Their main goal was to reduce the sizable risk that generic companies typically face when they sell at risk; the threat of triple damages, based on three times a generic drug’s sales.

Bristol-Myers and Sanofi negotiated away most of that threat, agreeing to limit damages to 50 percent of Apotex’s sales if their agreement was rejected. "

Read that line again!

You saw the right words. There is NO DOWNSIDE to Apotex to launch their generic, which of course they just did. And there is no wonder the analysts are calling for Mr. Dolan's head.

But it gets worse. For Mr. Dolan.

According to Reuters, "the latest sales data show that 78 percent of all new prescriptions filled for the blood clot medicine -- whose chemical name is clopidogrel -- on Aug. 18 were for the Apotex generic."

BMS sales have been virtually wiped out in just a few days!

"In terms of the number of total prescriptions written for the medicine -- which includes refills of old prescriptions and filling of new prescriptions -- the Apotex drug claimed a 65 percent share, with Plavix accounting for 35 percent. Hausman said the data were provided by IMS Health, which tracks prescription trends."

"the shelf life of the drug is "at least two years," so distributors and drugstores could be able to sell the cheaper generic for an extended period even if Bristol-Myers wins an injunction against future Apotex shipments to distributors."

Surely Mr. Dolan MUST be crying.

4 Comments:

Blogger Janine said...

So why did BMS go along with this? Does the head of Apotex have blackmail pictures of Mr. Dolan? Does Dolan secretly hold lots of Apotex stock? From what we currently know, the scenario makes no sense at all.

8/22/2006  
Blogger Peter Rost said...

Stupidity? OR worst luck in the world? Those are the options, according to WSJ.

8/22/2006  
Anonymous Anonymous said...

The Wall Street Journal didn't mention corporate arrogance. Oh well. Clearly David is beating Goliath.

Let's keep up the momentum. Thank you Dr. Rost for your commitment to this BLOG. There is a groundswell of intolerance for Pfizer's past corporate behavior forming in your wake.

8/23/2006  
Anonymous Anonymous said...

What is the missing piece? Dolan and company know something relative to the patent we don't, else why give away all your chips in negotiation?

8/30/2006  

Post a Comment

Links to this post:

Create a Link

<< Home